中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

146 records (took 0.027 seconds)

    FATTY ACID TREATMENT FOR CARDIAC PATIENTS
    72.
    发明申请
    FATTY ACID TREATMENT FOR CARDIAC PATIENTS 审中-公开
    脂肪酸治疗心脏病患者

    公开(公告)号：US20160296485A1

    公开(公告)日：2016-10-13

    申请号：US15188095

    申请日：2016-06-21

    Applicant: Baylor Research Institute

    Inventor： Charles R. ROE

    IPC: A61K31/20

    CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

    Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

    Abstract translation: 已经发现治疗需要治疗心脏病症的患者的方法包括向患者施用七碳脂肪酸化合物或其衍生物，其中所述化合物或其衍生物能够容易地进入线粒体而没有特殊的转运酶。 已经发现适合于治疗心脏或外科手术患者心脏组织的膳食制剂包括七碳脂肪酸链，其中七碳脂肪酸链的特征在于通过运输机制横向内线粒体膜的能力 其不需要肉碱棕榈酰转移酶I，肉碱棕榈酰转移酶II或肉碱/酰基肉毒碱转位酶和进行线粒体β-氧化的能力，并且其中所述化合物选自正庚酸或其衍生物，甘油三酯包含 正庚酸或其衍生物，三庚醇或其衍生物。

    Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
    74.
    发明申请
    Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease 审中-公开
    尿铁酸钠（GB3）作为心脏病标记物

    公开(公告)号：US20150342939A1

    公开(公告)日：2015-12-03

    申请号：US14729630

    申请日：2015-06-03

    Applicant: Baylor Research Institute

    Inventor： Raphael Schiffmann ,  Fanny Mochel ,  Lawrence Sweetman ,  Sabrina Fomi

    IPC: A61K31/445

    CPC classification number: A61K31/445 ,  A61B10/0051 ,  A61B10/0058 ,  A61B10/007 ,  A61B2010/0061 ,  G01N2030/8831

    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.

    Abstract translation: 本发明描述了非法布里病心脏病患者尿球蛋白神经酰胺（Gb3）水平的测定方法。 Gb3水平的测定提供了一种用于确定心脏病风险的筛选方法，并且可以通过使用药理学伴侣或其他药物降低Gb3水平来提供心脏疾病管理或心脏疾病风险缓解的替代治疗选择。

    BLOOD TRANSCRIPTIONAL SIGNATURES OF ACTIVE PULMONARY TUBERCULOSIS AND SARCOIDOSIS
    75.
    发明申请
    BLOOD TRANSCRIPTIONAL SIGNATURES OF ACTIVE PULMONARY TUBERCULOSIS AND SARCOIDOSIS 审中-公开
    活动性肺结核和肺结核的血液转录征

    公开(公告)号：US20150315643A1

    公开(公告)日：2015-11-05

    申请号：US14651989

    申请日：2013-12-13

    Applicant: BAYLOR RESEARCH INSTITUTE ,  MEDICAL RESEARCH COUNCIL ,  IMPERIAL COLLEGE HEALTHCARE NHS TRUST

    Inventor： Anne O'Garra ,  Chloe Bloom ,  Matthew Paul Reddoch Berry ,  Jacques F. Banchereau ,  Damien Chaussabel ,  Viginia Maria Pascual

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16

    Abstract: The present invention includes a method of determining a lung disease from a patient suspected of sarcoidosis, tuberculosis, lung cancer or pneumonia comprising: obtaining a sample from whole blood of the patient suspected of sarcoidosis, tuberculosis, lung cancer or pneumonia; detecting expression of (although not exclusive) six or more disease genes, markers, or probes selected from SEQ ID NOS.: 1 to 1446, wherein increased expression of mRNA of upregulated sarcoidosis, tuberculosis, lung cancer and pneumonia markers of SEQ ID NOS.: 1 to 1446 and/or decreased expression of mRNA of downregulated sarcoidosis, tuberculosis, lung cancer or pneumonia markers of SEQ ID NOS.: 1 to 1446 relative to the expression of the mRNAs from a normal sample; and determining the lung disease based on the expression level of the six or more disease markers of SEQ ID NOS.: 1 to 1446 based on a comparison of the expression level of sarcoidosis, tuberculosis, lung cancer, and pneumonia.

    Abstract translation: 本发明包括从疑似结节病，肺结核，肺癌或肺炎的患者中确定肺部疾病的方法，包括从疑似结节病，肺结核，肺癌或肺炎的患者的全血中获得样品; 检测选自SEQ ID NO：1至1446的（但不排除）六种或更多种疾病基因，标记或探针的表达，其中增加SEQ ID NO：1至1446的上调的结节病，结核病，肺癌和肺炎标记物的mRNA的表达。 ：1至1446和/或相对于来自正常样品的mRNA表达的SEQ ID NO：1至1446的下调的结节病，结核病，肺癌或肺炎标记物的mRNA的表达降低; 以及基于结节病，结核病，肺癌和肺炎的表达水平的比较，基于SEQ ID NO：1至1446的六种或更多种疾病标志物的表达水平确定肺部疾病。

    Micro RNA-148A as a Biomarker for Advanced Colorectal Cancer
    77.
    发明申请
    Micro RNA-148A as a Biomarker for Advanced Colorectal Cancer 审中-公开
    Micro RNA-148A作为高级结肠直肠癌的生物标志物

    公开(公告)号：US20130164279A1

    公开(公告)日：2013-06-27

    申请号：US13708537

    申请日：2012-12-07

    Applicant: BAYLOR RESEARCH INSTITUTE

    Inventor： Ajay Goel ,  C. Richard Boland ,  Masanobu Takahashi

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/178

    Abstract: The present invention includes methods of detection, diagnosis, prognosis, and treatment of a patient suspected of having a colorectal cancer comprising obtaining one or more samples of the patient, determining a level of expression of miR-148a or the level of methylation of a miR-148a promoter, and predicting a response to a cytotoxic chemotherapy cancer treatment.

    Abstract translation: 本发明包括对疑似患有结肠直肠癌的患者进行检测，诊断，预后和治疗的方法，包括获得患者的一个或多个样品，确定miR-148a的表达水平或miR的甲基化水平 -148a启动子，并预测对细胞毒性化疗癌症治疗的应答​​。

    FIVE AND FIFTEEN CARBON FATTY ACIDS FOR TREATING METABOLIC DISORDERS AND AS NUTRITIONAL SUPPLEMENTS
    78.
    发明申请
    FIVE AND FIFTEEN CARBON FATTY ACIDS FOR TREATING METABOLIC DISORDERS AND AS NUTRITIONAL SUPPLEMENTS 审中-公开
    用于治疗代谢障碍和营养补充剂的五味和碳酸脂肪酸

    公开(公告)号：US20130123359A1

    公开(公告)日：2013-05-16

    申请号：US13722020

    申请日：2012-12-20

    Applicant: Baylor Research Institute

    Inventor： Charles R. ROE

    IPC: A61K31/20 ,  A61K31/19

    CPC classification number: A61K31/20 ,  A23K20/158 ,  A23L33/12 ,  A23L33/40 ,  A61K31/19 ,  A61K31/202 ,  A61K31/22 ,  A61K31/225 ,  A61K31/23

    Abstract: According to the present invention, acquired metabolic derangements or fatty acid disorders in humans that are manifested by a deficiency in at least one enzyme involved in fatty acid metabolism are treated with a five carbon or a fifteen carbon fatty acid source. Rapid nutritional supplementation can also be provided to a mammalian cell by providing either a five carbon or fifteen carbon fatty acid source. Dietary formulations suitable for human consumption comprising either a five carbon fatty acid, a fifteen carbon fatty acid or triglycerides thereof is also disclosed.

    Abstract translation: 根据本发明，用五碳或十五碳脂肪酸源处理由脂肪酸代谢中涉及的至少一种酶的缺陷所表现的人类中获得的代谢紊乱或脂肪酸紊乱。 还可以通过提供五碳或十五碳脂肪酸源向哺乳动物细胞提供快速营养补充。 还公开了适合于人类消费的膳食制剂，其包含五碳脂肪酸，十五碳脂肪酸或其甘油三酸酯。

Patent Agency Ranking